Whether lorlatinib/lorlatinib targeted drug is included in medical insurance and its price

Lorlatinib/lorlatinib(Lorlatinib) is currently one of the first-line targeted drugs for the treatment of ALK-positive non-small cell lung cancer(NSCLC). Its unique pharmacological mechanism and high selectivity give it significant advantages in overcoming the resistance caused by previous generation ALK inhibitors (such as crizotinib and alectinib). The drug, developed by Pfizer, is a third-generation ALK/ROS1 tyrosine kinase inhibitor specifically used for patients who have developed resistance to previous ALK targeted therapies or have brain metastases.

According to the latest domestic medical insurance catalog information, lorlatinib has been officially included in the National Medical Insurance Category B Catalog, which means that patients can reimburse a certain percentage of the cost through medical insurance, which greatly eases the financial burden on families. The prerequisites for medical insurance reimbursement usually include pathological diagnosis, positive molecular test results, and the rationality and standardization of drug use.

In terms of price, the price of the original drug lorlatinib is relatively high. Common specifications in the domestic market are 25mg × 90 tablets and 100mg × 30 tablets, with the price of each box being about 20,000 yuan. However, after being included in medical insurance, the actual out-of-pocket payment of patients is greatly reduced. In addition, the price of original drugs in the Hong Kong market is relatively high, with a price range of about 30,000 to 50,000 yuan; in Turkey, due to the influence of local pharmaceutical policies and exchange rate factors, the price of original drugs is relatively low, about 10,000 yuan.

On the other hand, with the development of the global generic drug market, some generic versions of lorlatinib have gradually entered the market. For example, pharmaceutical factories in Laos and other places have produced imitations with ingredients and effects close to the original drugs, such as 100 mg × 30 tablets, and the price is roughly around 1,000 yuan. This provides an affordable treatment option for patients with limited economic conditions. However, when choosing generic drugs, special attention should be paid to regular sources and controllable drug quality. It is recommended to obtain them through pharmaceutical channels.

References：https://www.lorbrena.com/